How Mutation Status Affects Individualization of Treatment in mCRC

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.